Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle

Würdinger, Thomas; Deumelandt, Katrin; Vliet, Hans J. van der; Wesseling, Pieter; Gruijl, Tanja D. de

doi:10.1016/j.bbcan.2014.10.003

Cited by 37 publications

(34 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Functionally, TAMs in the GBM TME, are only producing low levels inflammatory cytokines and lack the ability to aid in T-cell responses via costimulation (38). In addition, they have been found to be great contributors to the immunosuppressive TME via release of soluble factors that dampen the immune response (39). Natural killer cells.…”

Section: Immune Cellular Componentsmentioning

confidence: 99%

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

Tomaszewski

Sánchez-Pérez

Gajewski

et al. 2019

Clinical Cancer Research

233

197

View full text Add to dashboard Cite

Glioblastoma (GBM) is a highly lethal brain tumor with poor responses to immunotherapies that have been successful in more immunogenic cancers with less immunosuppressive tumor microenvironments (TME). The GBM TME is uniquely challenging to treat due to tumor cellextrinsic components that are native to the brain, as well as tumor-intrinsic mechanisms that aid in immune evasion. Lowering the barrier of immunosuppression by targeting the genetically stable tumor stroma presents opportunities to treat the tumor in a way that circumvents the complications of targeting a constantly mutating tumor with tumor antigen-directed therapies. Tumor-associated monocytes, macrophages, and microglia are a stromal element of particular interest. Macrophages and monocytes compose the bulk of infiltrating immune cells and are considered to have protumor and immunosuppressive effects. Targeting these cells or other stromal elements is expected to convert what is considered the "cold" TME of GBM to a more "hot" TME phenotype. This conversion could increase the effectiveness of what have become conventional frontline immunotherapies in GBM-creating opportunities for better treatment through combination therapy.

show abstract

Section: Immune Cellular Componentsmentioning

confidence: 99%

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

Tomaszewski

Sánchez-Pérez

Gajewski

et al. 2019

Clinical Cancer Research

233

197

View full text Add to dashboard Cite

show abstract

“…Gliomas also secrete chemoattractants, which stimulate monocytes to enter the brain where they are converted to macrophages that, together with M2-activated microglia, set up a protective zone around the tumor (105). Once within the brain these myeloid cells actively take up GBM EVs, resulting in changes in their phenotype that are correlated, at least in part, with transfer of miRNAs, such as miR-451 and miR-21 (97).…”

Section: Brain Tumorsmentioning

confidence: 99%

Extracellular vesicles and intercellular communication within the nervous system

Zappulli¹,

Friis²,

Fitzpatrick³

et al. 2016

Journal of Clinical Investigation

193

168

View full text Add to dashboard Cite

“…Furthermore, in a series of 114 samples (62 patients) with brain lesions, tumour‐educated platelet analysis allowed correct identification of cancer patients in 91%, discrimination between primary and secondary tumours in 93% and discerned between the mutational subtypes in 82% . It has also to be remembered that blood components can actively promote glioma growth and malignancy, thus further studies investigating strategies to antagonize this cross‐talk are warranted .…”

Section: Tumour‐educated Plateletsmentioning

confidence: 99%

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours

Bertero

Siravegna

Rudà

et al. 2019

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

2019) Neuropathology and Applied Neurobiology 45, 655-670 Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours Tumour molecular profiling by liquid biopsy is being investigated for a wide range of research and clinical purposes. The possibility of repeatedly interrogating the tumour profile using minimally invasive procedures is helping to understand spatial and temporal tumour heterogeneity, and to shed a light on mechanisms of resistance to targeted therapies. Moreover, this approach has been already implemented in clinical practice to address specific decisions regarding patients' follow-up and therapeutic management. For central nervous system (CNS) tumours, molecular profiling is particularly relevant for the proper characterization of primary neoplasms, while CNS metastases can significantly diverge from primary disease or extra-CNS metastases, thus compelling a dedicated assessment. Based on these considerations, effective liquid biopsy tools for CNS tumours are highly warranted and a significant amount of data have been accrued over the last few years. These results have shown that liquid biopsy can provide clinically meaningful information about both primary and metastatic CNS tumours, but specific considerations must be taken into account, for example, when choosing the source of liquid biopsy. Nevertheless, this approach is especially attractive for CNS tumours, as repeated tumour sampling is not feasible. The aim of our review was to thoroughly report the state-of-the-art regarding the opportunities and challenges posed by liquid biopsy in both primary and secondary CNS tumours.

show abstract

Mechanisms of intimate and long-distance cross-talk between glioma and myeloid cells: How to break a vicious cycle

Cited by 37 publications

References 235 publications

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy

Extracellular vesicles and intercellular communication within the nervous system

Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours

Contact Info

Product

Resources

About